Jacob van Naarden - 09 Feb 2026 Form 4 Insider Report for ELI LILLY & Co (LLY)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Feb 2026, 16:25:13 UTC
Prior SEC filing
03 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file

Key filing fact

Jacob van Naarden filed Form 4 for ELI LILLY & Co (LLY) on 11 Feb 2026.

Key facts

  • This page summarizes Jacob van Naarden's Form 4 filing for ELI LILLY & Co (LLY).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 11 Feb 2026, 16:25.

Change

  • Previous filing in this sequence was filed on 03 Feb 2026.
  • Current net transaction value: +$5,083,247.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001661254 Primary reporting owner

Van Naarden Jacob

Relationship
EVP,Pres LLY Oncology&HdCorpBD
Address
LILLY CORPORATE CENTER, INDIANAPOLIS
Signature
/s/ Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file
Signature date
11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LLY transaction

Common Stock

Award

Transaction value
$5,083,247
Shares
+4,866
Change %
+22%
Price
$1044.67
Shares after
26,626
Date
09 Feb 2026
Ownership
Direct
LLY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,342
Date
09 Feb 2026
Ownership
Van Naarden Family Trust
Footnotes
F1
LLY holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,302
Date
09 Feb 2026
Ownership
By SLAT
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Footnote F2

On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .